Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase ...
Every woman has a one in 87 chance of getting ovarian cancer in her lifetime, and one in 130 will die from it. The symptoms of ovarian cancer — nausea, bloating, diarrhea, constipation, and discomfort ...
The study led by researchers at the National Institutes of Health (NIH), analysed deaths from breast, cervical, colorectal, lung and prostate cancers averted by prevention, screening ...